Does the media favor CLDX or HALO?

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 3 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.98 beat Celldex Therapeutics' score of 0.38 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Halozyme Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLDX or ALKS?

In the previous week, Alkermes had 11 more articles in the media than Celldex Therapeutics. MarketBeat recorded 14 mentions for Alkermes and 3 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 1.10 beat Celldex Therapeutics' score of 0.38 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, RGEN or CLDX?

Repligen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 10.09 $48.89M $0.90 146.69 Celldex Therapeutics $1.54M 1,652.88 -$258.76M -$4.26 N/A

Does the media refer more to RGEN or CLDX?

In the previous week, Repligen and Repligen both had 3 articles in the media. Repligen's average media sentiment score of 0.88 beat Celldex Therapeutics' score of 0.38 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CLDX or LGND?

In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 3 mentions for Celldex Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.43 beat Celldex Therapeutics' score of 0.38 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ligand Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CLDX or BCRX?

In the previous week, Celldex Therapeutics had 2 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for BioCryst Pharmaceuticals. Celldex Therapeutics' average media sentiment score of 0.38 beat BioCryst Pharmaceuticals' score of 0.00 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Celldex Therapeutics (CLDX) Competitors

$32.43 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$33.40 +0.97 (+2.99%)

As of 06/18/2026 07:58 PM Eastern

Compare

CLDX vs. HALO, ALKS, RGEN, LGND, and BCRX

Should you buy Celldex Therapeutics stock or one of its competitors? MarketBeat compares Celldex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celldex Therapeutics include Halozyme Therapeutics (HALO), Alkermes (ALKS), Repligen (RGEN), Ligand Pharmaceuticals (LGND), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Celldex Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 23.13% compared to Celldex Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 187.91% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Celldex Therapeutics currently has a consensus price target of $49.30, indicating a potential upside of 52.02%. Halozyme Therapeutics has a consensus price target of $81.60, indicating a potential upside of 19.04%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Celldex Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

Halozyme Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,652.88	-$258.76M	-$4.26	N/A
Halozyme Therapeutics	$1.40B	5.82	$316.89M	$2.78	24.66

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 3 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.98 beat Celldex Therapeutics' score of 0.38 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Halozyme Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Alkermes?

Celldex Therapeutics (NASDAQ:CLDX) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Alkermes has a net margin of 9.78% compared to Celldex Therapeutics' net margin of 0.00%. Alkermes' return on equity of 9.26% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Alkermes	9.78%	9.26%	5.66%

Celldex Therapeutics currently has a consensus target price of $49.30, indicating a potential upside of 52.02%. Alkermes has a consensus target price of $46.40, indicating a potential upside of 3.13%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76

In the previous week, Alkermes had 11 more articles in the media than Celldex Therapeutics. MarketBeat recorded 14 mentions for Alkermes and 3 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 1.10 beat Celldex Therapeutics' score of 0.38 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Alkermes shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Celldex Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,652.88	-$258.76M	-$4.26	N/A
Alkermes	$1.48B	5.08	$241.66M	$0.90	49.99

Summary

Alkermes beats Celldex Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Repligen?

Repligen (NASDAQ:RGEN) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Repligen and Repligen both had 3 articles in the media. Repligen's average media sentiment score of 0.88 beat Celldex Therapeutics' score of 0.38 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Repligen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	10.09	$48.89M	$0.90	146.69
Celldex Therapeutics	$1.54M	1,652.88	-$258.76M	-$4.26	N/A

Repligen currently has a consensus price target of $164.64, suggesting a potential upside of 24.71%. Celldex Therapeutics has a consensus price target of $49.30, suggesting a potential upside of 52.02%. Given Celldex Therapeutics' higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Repligen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

97.6% of Repligen shares are held by institutional investors. 0.6% of Repligen shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Repligen has a net margin of 6.73% compared to Celldex Therapeutics' net margin of 0.00%. Repligen's return on equity of 4.88% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Summary

Repligen beats Celldex Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Celldex Therapeutics (NASDAQ:CLDX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 3 mentions for Celldex Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.43 beat Celldex Therapeutics' score of 0.38 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celldex Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Celldex Therapeutics currently has a consensus price target of $49.30, suggesting a potential upside of 52.02%. Ligand Pharmaceuticals has a consensus price target of $257.71, suggesting a potential downside of 6.24%. Given Celldex Therapeutics' higher possible upside, research analysts clearly believe Celldex Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Ligand Pharmaceuticals has a net margin of 55.95% compared to Celldex Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Ligand Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,652.88	-$258.76M	-$4.26	N/A
Ligand Pharmaceuticals	$268.09M	20.55	$124.45M	$7.37	37.30

Summary

Ligand Pharmaceuticals beats Celldex Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to BioCryst Pharmaceuticals?

Celldex Therapeutics (NASDAQ:CLDX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

BioCryst Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,652.88	-$258.76M	-$4.26	N/A
BioCryst Pharmaceuticals	$874.84M	2.61	$263.86M	-$1.78	N/A

In the previous week, Celldex Therapeutics had 2 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for BioCryst Pharmaceuticals. Celldex Therapeutics' average media sentiment score of 0.38 beat BioCryst Pharmaceuticals' score of 0.00 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celldex Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Celldex Therapeutics currently has a consensus target price of $49.30, indicating a potential upside of 52.02%. BioCryst Pharmaceuticals has a consensus target price of $20.70, indicating a potential upside of 130.26%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Celldex Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Celldex Therapeutics' return on equity of -50.72% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Summary

Celldex Therapeutics beats BioCryst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLDX vs. The Competition

Export

Metric	Celldex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.55B	$3.41B	$6.42B	$12.59B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-7.61	19.73	24.78	24.44
Price / Sales	1,652.88	318.53	532.71	109.74
Price / Cash	N/A	127.84	45.07	55.09
Price / Book	4.09	8.16	10.80	6.58
Net Income	-$258.76M	$23.94M	$3.57B	$337.17M
7 Day Performance	3.71%	2.57%	0.72%	0.83%
1 Month Performance	6.05%	0.69%	0.41%	2.25%
1 Year Performance	58.20%	55.09%	29.34%	36.14%

Celldex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLDX Celldex Therapeutics	2.0104 of 5 stars	$32.43 flat	$49.30 +52.0%	+58.2%	$2.55B	$1.54M	N/A	150	High Trading Volume
HALO Halozyme Therapeutics	4.5845 of 5 stars	$71.28 +2.6%	$81.60 +14.5%	+29.8%	$8.24B	$1.40B	25.64	390	Analyst Forecast
ALKS Alkermes	2.6046 of 5 stars	$44.36 +0.2%	$46.13 +4.0%	+54.7%	$7.38B	$1.48B	49.29	2,050	Positive News Analyst Forecast
RGEN Repligen	3.6468 of 5 stars	$130.87 +0.2%	$164.64 +25.8%	+11.1%	$7.37B	$738.26M	145.41	2,000	News Coverage Positive News Gap Up
LGND Ligand Pharmaceuticals	2.4698 of 5 stars	$253.25 -0.9%	$257.71 +1.8%	+141.0%	$5.12B	$268.09M	34.36	80	Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLDX) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celldex Therapeutics (CLDX) Competitors

CLDX vs. HALO, ALKS, RGEN, LGND, and BCRX

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Summary

How does Celldex Therapeutics compare to Alkermes?

Summary

How does Celldex Therapeutics compare to Repligen?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Summary

How does Celldex Therapeutics compare to BioCryst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celldex Therapeutics (CLDX) Competitors

CLDX vs. HALO, ALKS, RGEN, LGND, and BCRX

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Which has more risk and volatility, CLDX or HALO?

Is CLDX or HALO more profitable?

Do analysts rate CLDX or HALO?

Which has better valuation and earnings, CLDX or HALO?

Does the media favor CLDX or HALO?

Do institutionals and insiders believe in CLDX or HALO?

Summary

How does Celldex Therapeutics compare to Alkermes?

Is CLDX or ALKS more profitable?

Do analysts rate CLDX or ALKS?

Does the media favor CLDX or ALKS?

Do insiders and institutionals believe in CLDX or ALKS?

Which has more risk & volatility, CLDX or ALKS?

Which has preferable valuation and earnings, CLDX or ALKS?

Summary

How does Celldex Therapeutics compare to Repligen?

Does the media refer more to RGEN or CLDX?

Which has higher earnings & valuation, RGEN or CLDX?

Do analysts rate RGEN or CLDX?

Which has more risk & volatility, RGEN or CLDX?

Do insiders and institutionals have more ownership in RGEN or CLDX?

Is RGEN or CLDX more profitable?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Does the media favor CLDX or LGND?

Which has more risk and volatility, CLDX or LGND?

Do insiders & institutionals believe in CLDX or LGND?

Do analysts rate CLDX or LGND?

Is CLDX or LGND more profitable?

Which has stronger valuation and earnings, CLDX or LGND?

Summary

How does Celldex Therapeutics compare to BioCryst Pharmaceuticals?

Which has higher valuation and earnings, CLDX or BCRX?

Does the media prefer CLDX or BCRX?

Which has more volatility and risk, CLDX or BCRX?

Do analysts prefer CLDX or BCRX?

Do institutionals & insiders believe in CLDX or BCRX?

Is CLDX or BCRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools